Zobrazeno 71 - 80
of 3 731
pro vyhledávání: ''
Autor:
Shidai Jin, Renhua Guo, Fangyan Gao, Liang Chen, Zhihong Zhang, Qianqian Wang, Jingya Zhang, Wen Gao, Fan Lin, Chen Zhang, Tianyu Qu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients har
Autor:
Yuhki Sakuraoka, Shozo Mori, Takayuki Shiraki, Yukihiro Iso, Takatsugu Matsumoto, Keiichi Kubota, Takamune Yamaguchi, Takayuki Shimizu, Kyung Hwa Park, Taku Aoki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:109-120
Recently, the number of patients with pancreatic ductal adenocarcinoma (PDAC) who have received both neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) has been increasing. However, whether adverse events (AEs) during AC influence the prog
Autor:
Bijan Zomorodbakhsch, Jutta Hübner, Andreas Hochhaus, Matthias Rengsberger, Tobias Rachow, Thomas Ernst, Michael Hartmann, Clemens P J G Wolf, Susan Foller
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The aim of our study was to analyse the frequency and severity of different types of potential interactions in oncological outpatients’ therapy. Therefore, medications, food and substances in terms of complementary and alternative medicine
Autor:
Josef Vodicka, Gabriela Krakorova, Jiri Blazek, Zuzana Teufelova, Magda Barinova, Karolina Hurdalkova, Marcela Buresova, Martin Svaton, Ondrej Topolcan, Miloš Pešek
Publikováno v:
Anticancer Research. 41:2053-2058
Aim To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with beva
Autor:
Natalie Andrews Wright, Prisni Rath, Trevor J. Pugh, Glenwood D. Goss, Gemma N Jones, Harmanjatinder S. Sekhon, Natalia Lukashchuk, Kayla Marsh, Bryan Lo, Paola Marco-Casanova, Laurence Bernard, William J. Howat, Dax Torti, Jonathon Torchia, Marc Duciaume, Alberto Leon, Darren Hodgson, Stanley E. Lazic, Johanne I Weberpals, Doreen Whelan, Alexander Fortuna, Martine P. Roudier
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 9, Pp 3045-3058 (2021)
Cancer Medicine, Vol 10, Iss 9, Pp 3045-3058 (2021)
Background In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum‐based chemotherapy. This study molecularly characterizes HGSOC patients from two distinct groups of chemotherapy responders (good vs.
Autor:
Jendrik Hardes, Arne Streitbürger, Stéphane Collaud, Theresa Stork, Rebecca Boemans, Christoph Pöttgen, Hans-Ulrich Schildhaus, Uta Dirksen, Clemens Aigner, Sebastian Bauer
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer
Background Pulmonary metastasectomy (PM) is an established treatment for selected patients with metastatic sarcomas. The aim of this study was to examine our institutional experience and evaluate factors predicting outcome. Methods We retrospectively
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e423-e427
Background In Canadian adults, follicular lymphoma (FL) is the most common subtype of non-Hodgkin lymphomas. Approximately 20% of patients with FL experience progression of disease within 2 years of first-line chemoimmunotherapy. Those patients have
Autor:
Aileen Deng, Jordan M. Winter, Charles J. Yeo, Chun Wang, Atrayee Basu Mallick, Steven J. Cohen, James Posey
Publikováno v:
European Journal of Cancer. 147:17-28
To compare overall survival (OS) in patients who underwent surgery for early-stage pancreatic adenocarcinoma (rPca) based on sequence (NAT, neoadjuvant therapy and/or AT, adjuvant therapy) and type (SA, single-agent or MA, multi-agent) of chemotherap
Autor:
Claudia Milena Agudelo, Sonia M. Hernandez, Vladimir Avila, Juan Felipe Combariza, Ana María Madera, Jaime Valdés, Leonardo Bautista, Fabián Andrés Mejía, Liliana Moreno, Rocio Orduz, Guillermo León, Marcos Arango, Carlos Alberto García Ramírez, Laura Díaz
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e365-e372
Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patien
Autor:
Shigeo Hisamori, Shigeru Tsunoda, Yasunori Deguchi, Hiroaki Hata, Dai Manaka, Yoshio Kadokawa, Yoshiharu Sakai, Kazutaka Obama, Hiroshi Okabe, Seiichiro Kanaya, Tatsuto Nishigori, Sachiko Minamiguchi, Daiju Yokoyama
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific Reports
IntroductionPoor Trastuzumab (Tmab) response in human epidermal growth factor receptor 2-overexpressing gastric or gastroesophageal junction adenocarcinoma (HER2-GEA) is reported to be associated with loss of phosphatase and tensin homolog (PTEN) exp